Status:
UNKNOWN
Development of a Genome-based Platform for Personalized Treatment in Locally Advanced Rectal Cancer Patients
Lead Sponsor:
Yonsei University
Conditions:
Locally Advanced Rectal Cancer
Eligibility:
All Genders
19+ years
Brief Summary
This study is aimed to develop a genome-based platform to predict patients who can achieve pathologic complete response after neoadjuvant treatment in locally advanced rectal cancer. The main treatmen...
Detailed Description
The treatment in this study is one of the standard treatments suggested by the NCCN guidelines. The patients received operation after neoadjuvant concurrent chemoradiotherapy and pathologic tumor resp...
Eligibility Criteria
Inclusion
- Patients older than 19 years old
- Clinically or histologically diagnosed rectal cancer (adenocarcinoma)
- Patients who satisfy all of the following conditions with either rectal cancer stage T3-4 or T2 in lower rectal cancer with any N stage according to 8th edition of American Joint Committee on Cancer
- \- Stage T3-4 (T2 in lower rectum) in CT or MRI
- Performance status 0 or 1 based on ECOG
- Patients agreed to provide the tissue sample
- Diseases can be evaluated according to RECIST Version 1.1
- Patients who voluntarily agreed to informed consent
Exclusion
- Patients with distant metastasis
- Patients with uncontrolled viral infection (HIV, HBV, HCV)
- Patient who are pregnant, or have possibility of pregnancy and are on lactating
- Hypersensitivity or history of allergic to the drug being used
- Patients with cerebrovascular disease, complications, and infections that are not medically controlled
- Patients with history of other malignant diseases within the past 5 years (excluding cured non-melanoma skin cancer or in situ cervical cancer)
- Those who are taking drugs that can cause drug interactions with chemotherapy
- Patients who withdraw consent
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 18 2025
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04738214
Start Date
February 1 2021
End Date
January 18 2025
Last Update
February 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University College of Medicine
Seoul, South Korea, 03722